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1. Health facilities included in this trial, location and date of launch of the intervention 
 
Clusters were antenatal care (ANC) clinics in health facilities. The 10 participating ANC clinics were selected purposely 
by the Ministry of Health (MOH) according to its programmatic activities and priorities and with geographical 
representation of the three regions of Mozambique (North, Center and South). Table S1 shows the health facilities listed 
chronologically according to the start of the intervention. It also shows the date of the launch of the intervention in each 
facility as well as its location. 
Table S1: Health facilities listed in chronological order according to the start of the intervention. The date of the 
launch of the intervention in each facility is also shown as well as well as its location. In addition, the table shows the 
approximate number of nurses providing ANC care in each facility and the number of first ANC visits attended in 2011. 
Order 
entered 
intervention 
Health Center (HC) Region and location Setting Number of first 
ANC visits 
attended in 
2011* 
Number of 
nurses proving 
ANC (approx.) 
Date launch 
intervention 
1 HC of Anchilo North: Nampula Province 
Rural 1894 2 June 2 2014 
2 HC N° 2 Central: Tete City Urban 2778 4 August 1 2014 
3 
HC annexed to the 
rural hospital of 
Songo 
Central: Tete 
Province 
Rural 
1281 2 October 3 2014 
4 
HC annexed to the 
district hospital of 
Dondo 
Central: Sofala 
Province 
Rural 
2728 4 November 28 2014 
5 HC da Matola II South: Maputo Province 
Urban 3276 6 January 30 2015 
6 HC 1ro de Maio South: Maputo City Urban 3165 2 April 8 2015 
7 
HC annexed to the 
rural hospital of 
Chowke 
South: Gaza Province 
Rural 
3480 6 June 4 2015 
8 
HC annexed to the 
rural hospital of 
Montepuez 
North: Cabo Delgado 
Province 
Rural 
4182 4 August 5 2015 
9 HC of Chibuto South: Gaza Province Rural 9756 6 October 1 2015 
10 HC 25 de Setembro North: Nampula city Urban 5960 8 December 4 2015 
* Data provided by the Ministry of Health. 
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2. Components of the ANC visits as per national guidelines 
 
National guidelines from the Ministry in Health of Mozambique promote an ANC model including a series of evidence-
based interventions for each ANC visit. Table S2 provides the interventions to be delivered to the women by ANC visit. 
Table S2: Elements/interventions in the ANC package of the Ministry of Health by ANC visit. 
No. Elements of ANC First ANC visit 
Follow-up 
ANC visit* 
1 Clinical physical examination X X 
2 Obstetric examination X X 
3 Measurement of haemoglobin level X From 32 weeks 
4 Assessing proteinuria X X 
5 Measurement of blood pressure X X 
6 Performance of syphilis test and treatment X  
7 Prevention of anaemia   
              7.1 Deworming (mebendazole) X  
              7.2 Ferrous sulfate + folic acid X X 
8 Malaria prevention   
              8.1 ITP (Sufadoxine-pyrimethamine) X X 
              8.2 Mosquito net X  
9 HIV testing & counselling  X 3 months after first test 
10 Vaccination X X 
11 Complementary intervention: Provision of ARV 
treatment 
X X 
  * Follow-up ANC visits are visits other than the first. 
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3. Components of Kit A and Kit B 
 
Table S3: Composition of Kit A 
 Product Pack size Quantity 
of packs 
1 Protein urine test strips 100 1 
2 HIV Rapid Diagnostic Test - Determine 100 1 
3 HIV Rapid Diagnostic Test – Unigold 20 1 
4 Syphilis Rapid Diagnostic Test 100 1 
5 Haemoglobin test strips 200 1 
6 Ampoule of penicillin benzathine 2,4 MIU 50 1 
7 Water for injection, 5ml ampoule 50 1 
8 Syringe 5 ml with 21G needle 100 1 
9 Mebendazole 500mg tablets 100 1 
10 Sufadoxine-pyrimethamanine 500-25mg 150 2 
11 Ferrous Sulphate/Folic Acid tablets (90/1) 1000 3 
12 Small tablet bags   100 1 
13 Latex examination gloves 100 2 
14 Disinfectant 0.5 litre 1 
15 Cotton wool 1 roll 1 
16 Lancet 200 1 
17 Chase buffers 1 2 
18 Capillary EDTA tubes 1 3 
 
Table S4: Composition of Kit B. 
 Product Pack size Quantity of 
packs 
1 Protein urine test strips  100 2 
2 HIV Rapid Diagnostic Test - Determine 100 1 
3 HIV Rapid Diagnostic Test – Unigold 20 1 
4 Sufadoxine-pyrimethamanine 500-25mg tablets 150 4 
5 Ferrous Sulphate/Folic Acid tablets (90/1) 1000 6 
6 Small tablet bags   500  1 
7 Haemoglobin test strips  200 1 
8 Latex examination gloves 100 4 
9 Disinfectant  0,5 litre 1 
10 Cotton wool  1 roll 1 
11 Lancet  200 1 
12 Chase buffers 1 1 
13 Capillary EDTA tubes 1 2 
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4. Photos of the kits 
 
Fig S1 and S2 present photos of Kit A; a ready-made box that is easily carried. 
Fig S1: Photo of an opened Kit A. 
 
Fig S2: Photo of the kits stacked. 
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5. Detailed list of outcomes and definitions 
 
For the purpose of the data analysis, the definitions of the outcomes had to be operationalized to be able to compute them 
from the data collected in the ANC logbook. For example, according to national guidelines for ANC, mebendazole 
should be given to women in the second or third trimester of pregnancy only. Under these guidelines, women were 
eligible to receive mebendazole if they had more than or equal to 12 weeks gestation and thus those at less than 12 weeks 
gestation were excluded from the denominator. Tables S5 and S6 list the outcomes and how they were defined and any 
other considerations for first and follow-up ANC visits, respectively. Section 12 of this Supplementary Appendix 
presents the logbook from where the data was extracted. 
Table S5: Primary and secondary outcomes in first ANC visits, definitions, considerations and variables used for 
their operationalization and calculation within the context of the ANC logbook in Section 12 of this 
Supplementary Appendix.  
Outcome Definition/considerations Eligible women (denominator) 
Screening practices 
Blood pressure measured in 1st 
visit 
• Proportion of eligible women who had blood pressure 
measured 
• Sphygmomanometer provided as part of the intervention 
All women attending the 1st ANC visit    
 
Proteinuria assessed in 1st visit • Proportion of eligible women who had proteinuria assessed 
• Dipsticks provided in the ANC kits 
All women attending the 1st ANC visit    
Syphilis rapid test performed 
in 1st visit 
• Proportion of eligible women who had a syphilis test 
performed 
• Syphilis rapid test provided in the ANC kits 
All women attending the 1st ANC  visit  
 
HIV test performed in 1st visit • Proportion of eligible women who had the HIV test performed 
• HIV rapid tests provided in the ANC kits (Determine® and 
Unigold®) 
All women whose HIV status in the 1st ANC visit 
was negative or unknown, and were not under 
treatment for HIV  
 
Haemoglobin measured in 1st 
visit 
• Proportion of eligible women who had haemoglobin levels 
measured 
• Haemoglobin colour scale tests provided in the ANC kits 
All women attending the 1st ANC visit  
Treatment/prevention practices 
Penicillin received in 1st visit 
(if syphilis positive)  
• Proportion of eligible women who were given the 1st dose of 
penicillin 
• Penicillin provided in the ANC kits 
All women who had a positive syphilis test in the 
1st ANC visit  
Antiretrovirals received in 1st 
visit (if HIV positive) 
• Proportion of eligible who were given antiretrovirals 
• Antiretrovirals were not provided in the ANC kits but were 
part of the intervention 
All women who had a positive HIV test in the 1st 
ANC visit  
Folic acid and ferrous sulfate 
received in 1st visit 
• All pregnant women should receive 1 iron pill per day. In 
practice they are given 30 pills at each appointment and are 
told to come back after 30 days. The fact that they received the 
pills is recorded in their hand-held record (caderneta); only 
when they receive the 3rd dose of 30 pills, it is registered in 
the ANC book. Thus, the logbook does not provide the 
information required for the analysis since it registers only the 
women that have received the 3rd dose (which is never in the 
1st ANC visit) 
• Folic acid/ferrous sulphate provided in ANC kit 
No computed 
Mebendazole received in 1st 
visit 
• Proportion of eligible women who were given mebendazole  
• According to the protocol of the MoH, mebendazole should 
only be given to women in the 2nd and 3rd trimester of 
pregnancy 
• Mebendazole provided in ANC kit 
All women at 13 weeks’ or more gestation age, 
attending the 1st ANC visit 
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Sulphadoxine- pyrimethamine 
received in 1st visit 
• Proportion of eligible women who were given fansidar  
• According to the protocol of the MoH, fansidar should not be 
given early in pregnancy. At the beginning of the trial the 
norm was to start at 20 weeks. At some point during the trial 
this changed to 12 weeks. Conservatively, we used the 20 
weeks as the cutoff throughout. 
• Fansidar should not be given to women who are HIV+ (if 
they are taking Cotrimoxazole and/or ART) 
All women at 20 weeks’ or more gestation age, 
who are not taking cotrimoxazol and/or ART, 
attending the 1st ANC visit   
 
Bed nets received in 1st visit • The bed nets were ANC Kit D so were part of the intervention 
but their supply was secured through other partners, and 
distribution by MoH 
• The trial only strengthened this intervention by reminding 
nurses in the refresher training 
• Major stock outs are rare but there were often short delays in 
distribution to health facilities. In these cases, nurses would 
give the woman her net on her follow-up visit.  
Not computed 
Tetanus toxoid received in 1st 
visit 
• The vaccine was not provided in the ANC kits 
• Stock outs are very rare in this item 
• What the trial did was to remind nurses in refresher training 
that they should vaccinate women; and in one center a cool 
box was provided so that they could vaccinate in all ANC 
rooms without having to refer the woman to another room. 
• Women that show they have been vaccinated previously (ie. 
By showing vaccination card or patient hand-held record 
(caderneta) should not be re-vaccinated. We would not expect 
100% of women to receive the vaccine. 
• Thus, the readings from the logbook are not adequate for the 
analysis of this outcome 
Not computed 
 
Table S6: Secondary outcomes in follow-up ANC visits, definitions and consideration for operationalization within 
the context of the ANC logbook shown in Section 12 of this Supplementary Appendix.  
Outcome Definition/considerations Eligible women (denominator) 
Screening practices 
Blood pressure measured in 
follow-up visits 
• Proportion of eligible women who had blood pressure 
measured 
• Sphygmomanometer provided as part of the intervention 
All women attending follow-up visits    
 
Proteinuria assessed in follow-
up visits 
• Proportion of eligible women who had proteinuria assessed 
• Dipsticks provided in the ANC kits 
All women attending follow-up visits    
Syphilis rapid test performed 
in follow-up visits 
• Not in follow-up visits according to national guidelines Not computed  
HIV test performed in follow-
up visits 
• Proportion of eligible women who had the HIV test performed 
• HIV rapid tests provided in the ANC kits (Determine® and 
Unigold®) 
All women whose HIV status in follow-up visits 
was negative or unknown, and were not under 
treatment for HIV  
 
Haemoglobin measured in 
follow-up visits 
• Proportion of eligible women who had haemoglobin levels 
measured 
• Haemoglobin colour scale tests provided in the ANC kits 
All women attending follow-up visits  
Treatment/prevention practices 
Penicillin received in follow-
up visits (if syphilis positive)  
• Not in follow-up visits according to national guidelines Not computed 
Antiretrovirals received in 
follow-up visits (if HIV 
positive) 
• Proportion of eligible who were given antiretrovirals 
• Antiretrovirals were not provided in the ANC kits but were 
part of the intervention 
All women who had a positive HIV test in follow-
up visits 
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Folic acid and ferrous sulfate 
received in follow-up visits 
• All pregnant women should receive 1 iron pill per day. In 
practice they are given 30 pills at each appointment and are 
told to come back after 30 days. The fact that they received the 
pills is recorded in their hand-held record (caderneta); only 
when they receive the 3rd dose of 30 pills, it is registered in 
the ANC book. Thus, the logbook does not provide the 
information required for the analysis since it registers only the 
women that have received the 3rd dose (which is never in the 
1st ANC visit) 
• Folic acid/ferrous sulphate provided in ANC kit 
Not computed 
Mebendazole received in 
follow-up visits 
• According to national guidelines, mebendazole is only given 
in the first ANC visit 
Not computed 
 
Sulphadoxine- pyrimethamine 
received in follow-up visits 
• Proportion of eligible women who were given fansidar  
• According to the protocol of the MoH, fansidar should not be 
given early in pregnancy. At the beginning of the trial the 
norm was to start at 20 weeks. At some point during the trial 
this changed to 12 weeks. Conservatively, we used the 20 
weeks as the cutoff throughout. 
• Fansidar should not be given to women who are HIV+ (if 
they are taking Cotrimoxazole and/or ART) 
All women at 20 weeks’ or more gestation age, 
who are not taking cotrimoxazol and/or ART, 
attending follow-up visits   
 
Bed nets received in follow-up 
visits 
• The bed nets were ANC Kit D so were part of the intervention 
but their supply was secured through other partners, and 
distribution by MoH 
• The trial only strengthened this intervention by reminding 
nurses in the refresher training 
• Major stock outs are rare but there were often short delays in 
distribution to health facilities. In these cases, nurses would 
give the woman her net on her follow-up visit.  
Not computed 
Tetanus toxoid received in 
follow-up visits 
• The vaccine was not provided in the ANC kits 
• Stock outs are very rare in this item 
• What the trial did was to remind nurses in refresher training 
that they should vaccinate women; and in one center a cool 
box was provided so that they could vaccinate in all ANC 
rooms without having to refer the woman to another room. 
• Women that show they have been vaccinated previously (ie. 
By showing vaccination card or patient hand-held record 
(caderneta) should not be re-vaccinated. We would not expect 
100% of women to receive the vaccine. 
• Thus, the readings from the logbook are not adequate for the 
analysis of this outcome 
Not computed 
 
6. Practice delivery rates at baseline (Step 1) 
 
Table S7. Practice delivery rates among first visits in step one, which was used to define the primary outcomes of the 
trial. 
 
 
n/N 
 
Rate 
      Screening for anaemia 1007/7792 12·9 
      Screening for proteinuria 951/7792 12·2 
      Treatment for worms (mebendazole) 2137/7225 30·1 
      Screening for high blood pressure 5457/7792 70·0 
      Preventive treatment for malaria 2089/3935 53·1 
      Screening for HIV 6836/7274 94·0 
      Treatment for HIV 562/638 88·1 
      Screening for syphilis 3260/7792 41·8 
      Treatment for syphilis 56/145 38·6 
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7. Data management and data quality assurance 
This was a pragmatic trial which used routine data as its primary data source. ANC nurses in Mozambique are required to 
register all antenatal visits in standardized logbooks which are designed and provided by the MOH. While the MOH 
compiles data from monthly summaries generated by the nurses on the basis of the data in the logbooks,  there is no 
system in place to systematically digitalize this information. Women have a hand-held record (caderneta) where the 
healthcare provider writes the information related to pregnancy. Women do not have clinical records, and the logbook 
was the only source document for the trial. Data management procedures were developed and implemented in all 10 
participating ANC clinics with the purpose of transferring the data in the logbook to the data management center. A 
simple coding system was introduced for the logbooks in order to avoid the ambiguities present in the standard system 
for completing the logbooks, and nurses were trained in how to complete the logbooks correctly using the coding system. 
Research assistants hired for the trial regularly reviewed the logbooks in each ANC clinic, took digital photos of each 
page of the logbook and sent them to the data management center in Maputo. We originally intended to link first and 
follow-up ANC visits for each woman by assigning a unique study subject ID at enrolment; however, implementation of 
such a system was in practice challenging and it is only available for a subset of the data. 
Several data quality audit and monitoring activities were implemented. Special consideration was taken to avoid bias due 
to changes in data quality associated with the implementation of the intervention. With this aim and to the extent 
possible, procedures and monitoring for data collection were deployed independently from the deployment and 
monitoring of the intervention.  
In order to minimize potential issues with quality of the routine data collected from the logbooks, three independent data 
monitoring procedures were implemented. First, we conducted routine monitoring visits to verify that the trial data 
collection instrument –the registration logbook– was being completed appropriately and that the data management 
processes were being done according to standardized procedures. These visits were conducted every two to three months 
in both control and intervention sites. Second, once in each ANC clinic, data monitors directly observed 100 consecutive 
first ANC visits per facility, and registered the results of tests and procedures in a monitoring log. The data in this 
monitoring log was then compared to the same records in the logbooks completed by the nurses. Third, a set of surveys 
was conducted by interviewing a sample of 100 consecutive women at each ANC clinic as they were leaving their first 
ANC visit. To compare data quality between the intervention and control periods, these data surveys were conducted at 
three different times – at the start, middle and end of the data collection period.  
Data management followed Good Clinical Practice (GCP) guidelines, and was implemented according to pre-defined 
HRP/WHO Standardized Operating Procedures (SOPs) for managing clinical trials. A more detailed description of these 
procedures can be found in the study protocol 11.  
8. Diagram of first and follow-up ANC visits independently 
 
Table S8: Trial diagram for first ANC visits. Each step equals 2 months except for step 1 which was 3 months. The 
ANC clinics are listed in Table S1 of this Supplementary Appendix.
 
 
1 2 3 4 5 6 7 8 9 10 11 Total
1 801 615 490 617 624 719 562 593 447 515 733 6716
2 998 613 703 836 879 769 728 644 717 934 906 8727
3 275 184 164 195 210 208 183 168 162 193 185 2127
4 1071 618 708 834 486 633 631 686 529 451 546 7193
5 793 441 283 603 566 182 698 678 755 831 761 6591
6 615 333 330 448 391 358 357 324 362 394 418 4330
7 412 305 370 392 377 408 470 414 349 392 389 4278
8 1285 979 962 905 950 1107 979 938 759 927 1055 10846
9 710 501 340 458 475 423 513 425 415 449 432 5141
10 832 946 911 1008 1381 1448 1124 1149 1209 1292 1349 12649
Total 7792 5535 5261 6296 6339 6255 6245 6019 5704 6378 6774 68598
Control Study Period Intervention Study Period
Clinics
Steps
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Table S9: Trial diagram for follow-up visits. Each step equals 2 months except for step 1 which was 3 months. The 
ANC clinics are listed in Table S1 of this Supplementary Appendix.
 
 
9. Effect of the intervention in follow-up antenatal care visits 
 
We originally intended to link first and follow-up ANC visits for each woman by assigning a unique study subject ID at 
enrolment; however, implementation of such a system was in practice challenging and it is only available for a subset of 
the data. In the analysis of follow-up ANC visits, women may contribute with more than one visit (i.e. repeated visits), 
and as such these observations are not independent. Since we were only able to identify repeated visits in a subset of 
women by using the unique subject ID, the main analysis was conducted without adjusting for repeating visits. However, 
a sensitivity analysis was conducted in this subset of women, including subject ID in the regression models as a random 
variable to assess the impact of the lack of independence of multiple observation on inference estimates. The impact of 
these adjustments on the precision of the estimates was very small. These analyses were computed by fitting generalized 
linear mixed models with the lme4 statistical package in R (version 3.1).  
Table S11 shows the effect of the intervention in secondary outcomes in follow-up visits. A statistically and clinically 
significant increase in practice coverage was observed in four of the six secondary outcomes evaluated in follow-up visits. 
Table S11 shows that 4015 of 85058 women (4·7%) were screened for anemia in the control period, as compared to 
48319 of 64621 women (74·8%) in the intervention period (adjusted odds ratio, 140·97; 99% CI, 123·60 to 160·79; 
P<0·001). For proteinuria, 2804 of 85058 women (3·3%) were screened for proteinuria in the control period, as compared 
to 59517 of 64621 women (92·1%) in the intervention period (adjusted odds ratio, 160·20; 99% CI, 136·37 to 188·19; 
P<0·001). For blood pressure, 57697 of 85058 women (67·8%) had their blood pressure measured in the control period, 
as compared to 64001 of 64621 women (99·0%) in the intervention period (adjusted odds ratio, 475·61; 99% CI, 398·70 
to 567·35; P<0·001). Preventive treatment for malaria (IPT) was provided to 35254 of 68045 women (51·8%) in the 
control period, as compared with 33610 of 52141 women (64·5%) in the intervention period (adjusted odds ratio, 1·37; 
99% CI, 1·30 to 1·45; P<0·001). 
For HIV practices in follow-up visits, the intervention did not have an effect. Table S11 shows that 522 of 75017 women 
(0·7%) was screened for HIV in the control period, as compared to 349 of 58009 women (0·6%) in the intervention 
period (adjusted odds ratio, 1·24; 99% CI, 0·90 to 1·70; P=0·005). Lastly, 30 of 54 HIV-positive women (55·6%) was 
treated with ARV in the control period, as compared to 15 of 25 women (60%) in the intervention period (adjusted odds 
ratio, 1·36; 99% CI, 0·25 to 7·34; P=0·068). 
The overall pattern of improvement is less dramatic in follow-up visit than in first visits. This is thought to be due to less 
clear national guidelines and protocols referring to follow-up visits. HIV repeat screening is only tested in some cases 
and HIV treatment continues at each visit. 
  
1 2 3 4 5 6 7 8 9 10 11 Total
1 1085 665 551 632 584 617 661 588 498 664 607 7152
2 2655 1537 1547 1668 1967 1932 1876 1746 1487 1646 1498 19559
3 1085 585 666 469 589 722 689 635 603 538 583 7164
4 2067 1445 1347 1025 1197 1428 1596 1706 1359 1166 1295 15631
5 1982 1487 685 1655 1504 1833 1784 1688 1459 1203 1463 16743
6 1909 1291 1115 1154 1412 1414 1306 1271 1142 1175 1195 14384
7 1104 988 951 918 1005 1068 936 929 916 965 989 10769
8 2226 1328 836 1274 1509 1586 1639 1655 1588 1293 1220 16154
9 2267 1315 1483 1071 1216 1305 1471 1581 1480 1086 1279 15554
10 2316 2688 1658 1722 2257 2204 2850 2834 2563 2649 2828 26569
Total 18696 13329 10839 11588 13240 14109 14808 14633 13095 12385 12957 149679
Control Study Period Intervention Study Period
Clinics
Steps
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Table S10. Effect of the intervention during follow-up antenatal care visits. 
 
 Control period 
 
Intervention period 
 
Mixed Model Adjusted Odds Ratio 
of Intervention Effect (99% CI) ‡ 
 
P Value 
  
ICC § 
  n/N Rate  n/N Rate     
             
 Screening for anaemia 4015/85058 4·7  48319/64621 74·8  140·97 123·60 160·79 0·0000  0·316 
 Screening for proteinuria 2804/85058 3·3  59517/64621 92·1  160·20 136·37 188·19 0·0000  0·210 
 Screening for high blood pressure 57697/85058 67·8  64001/64621 99·0  475·61 398·70 567·35 0·0000  0·540 
 Preventive treatment for malaria 35254/68045 51·8  33610/52141 64·5  1·37 1·30 1·45 0·0000  0·059 
 Screening for HIV 522/75017 0·7  349/58009 0·6  1·24 0·90 1·70 0·0851  0·005 
 Treatment for HIV 30/54 55·6  15/25 60·0  1·36 0·25 7·34 0·6412  0·068 
              
‡ Mixed model odds ratios account for the clustering of patients within clinics and adjust for time trends. Under the stepped-wedge design, the adjusted odds ratios are calculated with the use of all data points in the 
intervention period versus the control period and so represent the average odds of exposure to the intervention. 
§ Intracluster correlation coefficient during the control period 
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Figure S3. Outcome rates, by step and ANC clinic; follow-up ANC visits. Each cell contains the proportion of women 
who received each specific practice in the corresponding ANC clinic and step.  
 
*When the denominator to compute the cell rate is 0, cells are coloured in white. 
 
  
Steps (2 month periods) Steps (2 month periods)
1 2 3 4 5 6 7 8 9 10 11 1 2 3 4 5 6 7 8 9 10 11
A  Screening for Anaemia (N=148 679) B   Screening for proteinuria (N=149 679)
1 0 98 98 100 95 100 100 100 99 99 99 0 97 89 99 95 100 100 100 99 96 100
2 0 0 98 99 100 100 100 100 98 100 100 0 1 97 99 100 100 98 99 100 97 100
3 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
4 20 6 25 27 64 63 75 95 99 84 77 0 0 0 3 71 88 87 98 99 98 96
5 0 0 0 0 3 29 38 38 27 38 28 0 0 0 0 4 80 92 88 97 98 97
6 0 0 1 0 0 0 65 100 100 99 100 0 0 0 0 0 0 64 100 99 100 100
7 0 1 2 5 1 2 1 28 2 8 8 0 0 0 0 0 1 0 42 95 100 92
8 0 1 0 0 3 0 0 2 94 41 66 0 0 0 0 2 0 0 2 92 77 96
9 0 0 0 0 0 0 0 1 1 41 5 0 0 0 0 0 0 0 1 1 64 80
10 0 0 0 1 0 2 2 3 2 1 70 0 0 0 1 0 1 2 1 2 1 72
C  Screening for high blood pressure (N= 149 679) D  Treatment for malaria (120 186)
1 50 99 96 100 94 100 100 100 100 99 100 36 85 83 87 79 80 88 90 88 88 84
2 1 2 97 100 100 100 100 100 100 99 100 53 61 75 77 66 60 64 55 52 59 63
3 100 100 100 100 100 100 100 100 100 100 100 38 48 42 58 54 41 47 44 38 68 54
4 100 99 65 100 95 98 97 100 100 99 98 52 49 57 47 55 51 48 42 40 48 44
5 100 100 100 97 28 100 97 100 100 100 100 6 19 61 70 42 80 83 86 75 67 73
6 100 98 99 100 100 100 100 100 100 100 100 18 20 52 67 42 39 52 49 56 49 34
7 83 100 100 71 100 94 96 100 100 100 100 54 65 50 54 56 41 64 72 86 67 83
8 69 90 94 99 100 100 99 100 100 98 100 69 67 79 87 81 73 78 77 78 79 67
9 87 58 99 72 52 62 99 99 99 100 99 28 47 56 54 31 63 56 53 40 52 53
10 60 33 4 26 3 8 30 16 42 41 95 44 0 40 70 68 73 63 63 37 70 71
E   Screening for HIV (N=133 026) F   Treatment for HIV (N=79)*
1 4 3 1 2 1 1 1 0 0 0 0 50 0 0 100
2 2 3 1 2 2 0 3 0 1 0 0 67 100 100 100 0 67
3 0 1 0 0 2 1 0 0 1 0 0 100 100
4 0 0 0 0 0 1 0 0 1 1 1 67 0 100 50 100
5 0 0 0 0 2 0 0 0 0 0 0 100
6 0 1 0 1 0 0 0 0 0 0 0 100 100 100
7 0 0 0 1 0 1 0 1 1 0 0 100 0 50
8 1 0 0 0 0 0 0 0 0 0 1 100 0 0
9 0 0 0 0 0 0 0 0 0 0 0 100
10 3 1 1 2 2 1 2 1 0 1 1 50 0 50 25 50 0 57 50 100 100
Cl
in
ic
s
Cl
in
ic
s
Cl
in
ic
s
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10. Effect of the intervention in composite outcome 
 
We computed this score for first ANC visits and included practices targeting all or most women as opposed to practices 
that are intended for a small subgroup such as treatment for syphilis or HIV. To compute this score, one point was added 
for each intended screening or treatment intervention delivered during the ANC visits. The practices included in the score 
were screening for high blood pressure, proteinuria, anaemia, syphilis and HIV, and treatment for parasitic worms. These 
add up to a maximum score value of six points. 
The intervention was also found to have a statistically significant effect on the composite outcome score (adjusted mean 
difference 1·72; 99% CI 1·70–1·74; p<0·0001). 
 
Figure S4. Composite outcome score, by step and ANC clinic; first ANC visits. 
 
 
 
11. Ethical aspects of the trial 
 
This protocol has been approved by the Comité Nacional de Bioéticapara a Saúde of the Ministry of Health in 
Mozambique. In addition, it has been approved by the Research Project Review Panel of the 
UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in 
Human Reproduction at the Department of Reproductive Health and Research of WHO, and the WHO Research Ethics 
Review Committee, Geneva, Switzerland.  
A waiver of consent forms for participating women was obtained since this study is considered of minimal risk (risks of 
daily life, and includes the risks associated with routine physical examinations and review of medical records) and it is 
developed in the context of regular prenatal care and using as research records those used in health care process (no data 
collection tools have been developed to gather data regarding women´s health for the study). Recommendations provided 
for The Ottawa Statement on the Ethical Design and Conduct of Cluster Randomized Trials were taken into account in 
the design of this trial. 
  
 
1 2 3 4 5 6 7 8 9 10 11
1 2.4 5.7 5.7 5.9 5.8 5.9 5.9 5.9 5.9 5.8 5.9
2 1.6 2.3 5.7 5.7 5.4 5.6 5.7 5.8 5.6 5.7 5.7
3 5.2 5.6 5.7 5.2 5.5 5.3 5.4 5.6 5.6 5.5 5.6
4 2.7 3.0 2.8 3.1 5.6 5.4 5.4 5.5 5.5 5.5 5.6
5 4.4 4.1 5.1 5.3 4.7 5.8 5.7 5.6 5.6 5.6 5.7
6 2.4 2.7 3.5 3.4 3.6 3.7 4.9 5.5 5.6 5.5 5.6
7 1.8 3.1 3.5 3.1 3.5 3.7 3.3 5.5 5.7 5.6 5.6
8 2.4 2.5 2.6 3.2 3.0 2.7 2.6 3.0 5.3 5.6 5.7
9 2.2 4.1 4.8 4.6 4.0 3.6 3.7 3.5 3.8 5.7 5.7
10 1.8 2.1 2.1 2.7 2.3 2.6 2.7 2.4 2.1 2.2 4.9
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12. Checklist of items to be included when reporting a cluster randomized controlled trial 
 
Section/Topic Item 
No 
Standard Checklist item Extension for cluster designs Page 
No. 
Title and abstract  
 1a Identification as a randomised trial in 
the title 
Identification as a cluster randomised trial in 
the title 
1 
1b Structured summary of trial design, 
methods, results, and conclusions (for 
specific guidance see CONSORT for 
abstracts) 
 5 
Introduction  
Background and 
objectives 
2a Scientific background and explanation 
of rationale 
Rationale for using a cluster design 8-9 
2b Specific objectives or hypotheses Whether objectives pertain to the cluster 
level, the individual participant level or both 
8-9 
Methods  
Trial design 3a Description of trial design (such as 
parallel, factorial) including allocation 
ratio 
Definition of cluster and description of how 
the design features apply to the clusters 
8-9 
3b Important changes to methods after 
trial commencement (such as 
eligibility criteria), with reasons 
 - 
Participants 4a Eligibility criteria for participants Eligibility criteria for clusters  8-9 
4b Settings and locations where the data 
were collected 
 8-9 
Suppl. Appendix 
Section 1 
Interventions 5 The interventions for each group with 
sufficient details to allow replication, 
including how and when they were 
actually administered 
Whether interventions pertain to the cluster 
level, the individual participant level or both 
9 
Outcomes 6a Completely defined pre-specified 
primary and secondary outcome 
measures, including how and when 
they were assessed 
Whether outcome measures pertain to the  
cluster level, the individual participant level 
or both 
11 
6b Any changes to trial outcomes after 
the trial commenced, with reasons 
 11 
Sample size 7a How sample size was determined Method of calculation, number of clusters(s) 
(and whether equal or unequal cluster sizes 
are assumed), cluster size, a coefficient of 
intracluster correlation (ICC or k), and an 
indication of its uncertainty 
12-13 
7b When applicable, explanation of any 
interim analyses and stopping 
guidelines 
 12-13 
Randomisation:  
 Sequence generation 8a Method used to generate the random 
allocation sequence 
 12 
8b Type of randomisation; details of any 
restriction (such as blocking and block 
size) 
Details of stratification or matching if used - 
 Allocation concealment 
mechanism 
9 Mechanism used to implement the 
random allocation sequence (such as 
sequentially numbered containers), 
describing any steps taken to conceal 
the sequence until interventions were 
assigned 
Specification that allocation was based on 
clusters rather than individuals and whether 
allocation concealment (if any) was at the 
cluster level, the individual participant level 
or both 
11 
 Implementation 
 
10 Who generated the random allocation 
sequence, who enrolled participants, 
and who assigned participants to 
interventions 
Replace by 10a, 10b and 10c  
 10a  Who generated the random allocation 
sequence, who enrolled clusters, and who 
assigned clusters to interventions 
 
8-9, 12 
 10b  Mechanism by which individual participants 
were included in clusters for the purposes of 
the trial (such as complete enumeration, 
random sampling) 
8-9 
 10c  From whom consent was sought 
(representatives of the cluster, or individual 
Suppl. Appendix 
Section 11 
15 
 
cluster members, or both), and whether 
consent was sought before or after 
randomisation 
     
Blinding 11a If done, who was blinded after 
assignment to interventions (for 
example, participants, care providers, 
those assessing outcomes) and how 
 - 
11b If relevant, description of the 
similarity of interventions 
 10-11 
Statistical methods 12a Statistical methods used to compare 
groups for primary and secondary 
outcomes 
How clustering was taken into account 12-13 
12b Methods for additional analyses, such 
as subgroup analyses and adjusted 
analyses 
 12-13 
Results  
Participant flow (a 
diagram is strongly 
recommended) 
13a For each group, the numbers of 
participants who were randomly 
assigned, received intended treatment, 
and were analysed for the primary 
outcome 
For each group, the numbers of clusters that 
were randomly assigned, received intended 
treatment, and were analysed for the primary 
outcome 
13 
13b For each group, losses and exclusions 
after randomisation, together with 
reasons 
For each group, losses and exclusions for 
both clusters and individual cluster members 
13-14 
Recruitment 14a Dates defining the periods of 
recruitment and follow-up 
 13 and Suppl. 
Appendix Section 1 
14b Why the trial ended or was stopped  - 
Baseline data 15 A table showing baseline 
demographic and clinical 
characteristics for each group 
Baseline characteristics for the individual 
and cluster levels as applicable for each 
group 
Table 3 
Numbers analysed 16 For each group, number of 
participants (denominator) included in 
each analysis and whether the analysis 
was by original assigned groups 
For each group, number of clusters included 
in each analysis 
13-14 
Outcomes and 
estimation 
17a For each primary and secondary 
outcome, results for each group, and 
the estimated effect size and its 
precision (such as 95% confidence 
interval) 
Results at the individual or cluster level as 
applicable and a coefficient of intracluster 
correlation (ICC or k) for each primary 
outcome 
Table 4 
17b For binary outcomes, presentation of 
both absolute and relative effect sizes 
is recommended 
 Table 4 
Ancillary analyses 18 Results of any other analyses 
performed, including subgroup 
analyses and adjusted analyses, 
distinguishing pre-specified from 
exploratory 
 Table 4 and Suppl. 
Appendix Sections 9 
and 10 
Harms 19 All important harms or unintended 
effects in each group (for specific 
guidance see CONSORT for harmsi) 
 - 
Discussion  
Limitations 20 Trial limitations, addressing sources 
of potential bias, imprecision, and, if 
relevant, multiplicity of analyses 
 17 
Generalisability 21 Generalisability (external validity, 
applicability) of the trial findings 
Generalisability to clusters and/or individual 
participants (as relevant) 
18 
Interpretation 22 Interpretation consistent with results, 
balancing benefits and harms, and 
considering other relevant evidence 
 18 
Other information   
Registration 23 Registration number and name of trial 
registry 
 6 
Protocol 24 Where the full trial protocol can be 
accessed, if available 
 7-8 and reference 14 
Funding 25 Sources of funding and other support 
(such as supply of drugs), role of 
funders 
 6 
 
  
16 
 
13. Data collection instrument: ANC logbook 
Fig S5: Page 1 (left page) of the Mozambique national ANC logbook (each row represent one ANC visit). 
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Fig S6: Page 2 of the Mozambique national ANC logbook (each row represent one ANC visit).  
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